{"9CS0ysIAAAAJ": [["Harry Suryapranata", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Chun-Chin Chang", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Neville Kukreja", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Norihiro Kogame", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Kuniaki Takahashi", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Simon Walsh", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Ply Chichareon", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Scot Garg", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Philippe Gabriel Steg", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Jan J Piek", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Marco Valgimigli", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Christian Hamm", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Rodrigo Modolo", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Joanna Wykrzykowska", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Yoshinobu Onuma", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Rene Koning", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Stephan Windecker", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Mariusz Tomaniak", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Hideyuki Kawashima", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["James Cotton", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Ibrahim Akin", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Patrick W Serruys", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Pascal Vranckx", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["Masafumi Ono", 2020, "DAPT score and the impact of ticagrelor monotherapy during the second year after PCI"], ["ESC Committee for Practice Guidelines (CPG", 2020, "Corrigendum to\" 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk\"[Atherosclerosis 290 (2019) 140-205]."], ["Force Members Task", 2020, "Corrigendum to\" 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk\"[Atherosclerosis 290 (2019) 140-205]."], ["Bruno R da Costa", 2020, "Whole milk compared with reduced-fat milk and childhood overweight: a systematic review and meta-analysis"], ["Kevin E Thorpe", 2020, "Whole milk compared with reduced-fat milk and childhood overweight: a systematic review and meta-analysis"], ["Jonathon L Maguire", 2020, "Whole milk compared with reduced-fat milk and childhood overweight: a systematic review and meta-analysis"], ["Deborah L O'Connor", 2020, "Whole milk compared with reduced-fat milk and childhood overweight: a systematic review and meta-analysis"], ["Shelley M Vanderhout", 2020, "Whole milk compared with reduced-fat milk and childhood overweight: a systematic review and meta-analysis"], ["Mary Aglipay", 2020, "Whole milk compared with reduced-fat milk and childhood overweight: a systematic review and meta-analysis"], ["Catherine S Birken", 2020, "Whole milk compared with reduced-fat milk and childhood overweight: a systematic review and meta-analysis"], ["Nazi Torabi", 2020, "Whole milk compared with reduced-fat milk and childhood overweight: a systematic review and meta-analysis"], ["Carina Blomstr\u00f6m-Lundqvist", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Georgia Sarquella-Brugada", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Antonio Zaza", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Josep Brugada", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Gerhard-Paul Diller", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Piotr Suwalski", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Andrew Grace", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Juan-Carlos Kaski", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Frederic Sacher", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Bulent Gorenek", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Juan J Gomez-Doblas", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Karl-Heinz Kuck", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Siew Yen Ho", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Jeroen J Bax", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Spyridon G Deftereos", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Fernando Arribas", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Domenico Corrado", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Hugh Calkins", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Elena Arbelo", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Demosthenes G Katritsis", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Pier David Lambiase", 2020, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the \u2026"], ["Benno JWM Rensing", 2020, "The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing \u2026"], ["Joanna J Wykrzykowska", 2020, "The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing \u2026"], ["Ren\u00e9 Koning", 2020, "The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing \u2026"], ["Hironori Hara", 2020, "The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing \u2026"], ["Chao Gao", 2020, "The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing \u2026"], ["Pedro Canas da Silva", 2020, "The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing \u2026"], ["Robert F Storey", 2020, "The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing \u2026"], ["Rutao Wang", 2020, "The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing \u2026"], ["Zsolt K\u0151szegi", 2020, "Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS \u2026"], ["Roberto Botelho", 2020, "Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS \u2026"], ["Eric Eeckhout", 2020, "Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS \u2026"], ["Andres I\u00f1iguez", 2020, "Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS \u2026"], ["Diana Trendafilova-Lazarova", 2020, "Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS \u2026"], ["Sjoerd Hofma", 2020, "Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS \u2026"], ["Claudia Quammie", 2020, "Paediatric reference values for total psoas muscle area"], ["Manuela Perez", 2020, "Paediatric reference values for total psoas muscle area"], ["Gerald Lebovic", 2020, "Paediatric reference values for total psoas muscle area"], ["Jessica P Woolfson", 2020, "Paediatric reference values for total psoas muscle area"], ["Hiten Patel", 2020, "Paediatric reference values for total psoas muscle area"], ["Govind B Chavhan", 2020, "Paediatric reference values for total psoas muscle area"], ["Paul W Wales", 2020, "Paediatric reference values for total psoas muscle area"], ["Eberhard Lurz", 2020, "Paediatric reference values for total psoas muscle area"], ["Vicky L Ng", 2020, "Paediatric reference values for total psoas muscle area"], ["Binita M Kamath", 2020, "Paediatric reference values for total psoas muscle area"], ["Amanda Ricciuto", 2020, "Paediatric reference values for total psoas muscle area"], ["Bianca Rocca", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Francesco Cosentino", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Maddalena Lettino", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Naveed Sattar", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Carl J \u00d6stgren", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["David C Wheeler", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Petar M Seferovi\u0107", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Linda G Mellbin", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Antonio Ceriello", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Nikolaus Marx", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Marco Roffi", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Miguel Sousa-Uva", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Peter J Grant", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Clifford J Bailey", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Victor Aboyans", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Heikki V Huikuri", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Massimo Federici", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Paul Valensi", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Diederick E Grobbee", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Tina Birgitte Hansen", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Victoria Delgado", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Isabelle Johansson", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Gerasimos Filippatos", 2020, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and \u2026"], ["Robert Jan van Geuns", 2020, "Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS \u2026"], ["Rod H Stables", 2020, "Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS \u2026"], ["Angel Cequier", 2020, "Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS \u2026"], ["Keith Oldroyd", 2020, "Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS \u2026"], ["Chun Chin Chang", 2020, "Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS \u2026"], ["Kees-Jan Royaards", 2020, "Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS \u2026"], ["Roxana Mehran", 2020, "Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial"], ["Luc Maillard", 2020, "Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial"], ["Laura Kerkmeijer", 2020, "Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial"], ["Peter Barlis", 2020, "Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial"], ["Tiziano Moccetti", 2020, "Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial"], ["Hidenori Komiyama", 2020, "Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial"], ["Suneel Talwar", 2020, "Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial"], ["Antonio Colombo", 2020, "Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial"], ["Andrew D Pinto", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Navindra Persaud", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Michael R Law", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Muhammad M Mamdani", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Michael Bedard", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Baiju R Shah", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Andrew S Boozary", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Frank Sullivan", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Norman Umali", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Stephen W Hwang", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Tara Gomes", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Richard H Glazier", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Andreas Laupacis", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Steven G Morgan", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Braden J Manns", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Karen Tu", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Paul I Oh", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Danielle Martin", 2020, "Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN meds randomized clinical trial"], ["Ian M Graham", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Marc S Sabatine", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Alberico L Catapano", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Guy G De Backer", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Terje R Pedersen", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Lale Tokgozoglu", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Konstantinos C Koskinas", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Manuela Casula", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Marja-Riitta Taskinen", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Borislava Mihaylova", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Colin Baigent", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Ulf Landmesser", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Olov Wiklund", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Dimitrios J Richter", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Lina Badimon", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Brian A Ference", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["M John Chapman", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Gabriele Riccardi", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Alison Halliday", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["Fran\u00e7ois Mach", 2020, "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of \u2026"], ["James J Jung", 2020, "First-year analysis of the operating room black box study"], ["Teodor Grantcharov", 2020, "First-year analysis of the operating room black box study"], ["Martin Leon", 2019, "Will the PARTNER 3 Low Risk Trial change my practice?"], ["Hannah McConkey", 2019, "Will the PARTNER 3 Low Risk Trial change my practice?"], ["Azeem Latib", 2019, "Will the PARTNER 3 Low Risk Trial change my practice?"], ["Thomas Modine", 2019, "Will the PARTNER 3 Low Risk Trial change my practice?"], ["Michael J Reardon", 2019, "Will the Evolut Low Risk trial change my practice?"], ["Crochan J O'Sullivan", 2019, "Will the Evolut Low Risk trial change my practice?"], ["P J\u00fcni", 2019, "Will the Evolut Low Risk trial change my practice?"], ["Hendrik Treede", 2019, "Will the Evolut Low Risk trial change my practice?"], ["L S\u00f8ndergaard", 2019, "Will the Evolut Low Risk trial change my practice?"], ["Stephen Hoole", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Farzin Fath\u2010Ordoubadi", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Keith G Oldroyd", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Philippe G Steg", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Saqib Chowdhary", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Gavin Galasko", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Chun\u2010Chin Chang", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Christian W Hamm", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Azfar Zaman", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Richard Anderson", 2019, "Impact of established cardiovascular disease on outcomes in the randomized global leaders trial"], ["Rajan Mahto", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Martina Rothenbuhler", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Keshar Gurung", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Naveen Pandey", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Dhungana Sahadeb", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Surendra Uranw", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Prashant Shah", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Peter Juni", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Thomas Pilgrim", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Krishna Agrawal", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Santosh Bastola", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Nikesh Shres-Tha", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Prahlad Karki", 2019, "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese School Children: Cluster Randomized Comparison"], ["Peter Jueni", 2019, "Ticagrelor Monotherapy versus Standard Dual Antiplatelet Therapy After Drug-Eluting Coronary Stent Implantation: A Systematic Review and Individual Patient Data Meta-Analysis \u2026"], ["Jan GP Tijssen", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["RM van Geuns", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Tessa Rademaker-Havinga", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Pawel E Buszman", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Krzysztof Zmudka", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Janusz Prokopczuk", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Manel Sabat\u00e9", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Tobias Geisler", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Veselin Valkov", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Marcello Dominici", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Usman Baber", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Ernest Spitzer", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Clemens Steinwender", 2019, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial."], ["Robert-Jan van Geuns", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Rui Cruz Ferreira", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Bernhard Frey", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Stephen P Hoole", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Amanda Sousa", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Tian Hai Koh", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Osama Soliman", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Olivier F Bertrand", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Tommaso Gori", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Aris Moschovitis", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Sing-Chien Yap", 2019, "Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)"], ["Marco Valgimgli", 2019, "Dyspnoea in the GLOBAL LEADERS trial reply"], ["Patrick Serruys", 2019, "Dyspnoea in the GLOBAL LEADERS trial reply"], ["R McManus", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["EA Rosei", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["G Mancia", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["G de Simone", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["SE Kjeldsen", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["E Shlyakhto", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["B Williams", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["V Aboyans", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["K Narkiewicz", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["M Kerins", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["J Redon", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["RE Schmieder", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["DL Clement", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["A Coca", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["W Spiering", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["GYH Lip", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["I Desormais", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["A Dominiczak", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["R Kreutz", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["M Burnier", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["F Ruschitzka", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["C Tsioufis", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["L Ruilope", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["T Kahan", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["M Azizi", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["A Zanchetti", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["S Laurent", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["F Mahfoud", 2019, "Wytyczne ESC/ESH dotycz\u0105ce post\u0119powania w nadci\u015bnieniu t\u0119tniczym (2018)= 2018 ESC/ESH Guidelines for the management of arterial hypertension"], ["Karine Toupin April", 2019, "Tramadol for osteoarthritis"], ["Anne WS Rutjes", 2019, "Tramadol for osteoarthritis"], ["Tania El Hindi", 2019, "Tramadol for osteoarthritis"], ["Jennifer Vincent", 2019, "Tramadol for osteoarthritis"], ["Peter Tugwell", 2019, "Tramadol for osteoarthritis"], ["George A Wells", 2019, "Tramadol for osteoarthritis"], ["Vivian Welch", 2019, "Tramadol for osteoarthritis"], ["Jacinthe Bisaillon", 2019, "Tramadol for osteoarthritis"], ["Lara J Maxwell", 2019, "Tramadol for osteoarthritis"], ["M Elaine Husni", 2019, "Tramadol for osteoarthritis"], ["Stephane Fournier", 2019, "Allogeneic BK Virus\u2013Specific T Cells for PML"], ["Bernard De Bruyne", 2019, "Allogeneic BK Virus\u2013Specific T Cells for PML"], ["Subodh Verma", 2019, "De-intensified treatment in human papillomavirus-positive oropharyngeal cancer"], ["C David Mazer", 2019, "De-intensified treatment in human papillomavirus-positive oropharyngeal cancer"], ["Auer Reto", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Dik Heg", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Rodondi Nicolas", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Thomas F L\u00fcscher", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Lorenz R\u00e4ber", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["David Carballo", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Christian M Matter", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["David Nanchen", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Roland Klingenberg", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Olivier Muller", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Pierre-Fr\u00e9d\u00e9ric Keller", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Baris Gencer", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Sebastian Carballo", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Francois Mach", 2019, "Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention"], ["Darrel P Francis", 2019, "PCI guided by fractional flow reserve at 5 years"], ["Brahmajee K Nallamothu", 2019, "PCI guided by fractional flow reserve at 5 years"], ["Manfred B Wischnewsky", 2019, "Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography"], ["Willibald Maier", 2019, "Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography"], ["Slayman Obeid", 2019, "Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography"], ["Philipp Jakob", 2019, "Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography"], ["Barbara E St\u00e4hli", 2019, "Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography"], ["Sai G Lambotharan", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Hwee Teoh", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Arun C Partridge", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Christopher Bonneau", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Naveen Gupta", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Deepak L Bhatt", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Olugbenga O Bello", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["David W Dai", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Ehab Bakbak", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Shaun G Goodman", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Bernard Zinman", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Erika Opingari", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Andrew T Yana", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Adrian Quan", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Tamique Mason", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Andrew H Williams", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Michael E Farkouh", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Ronald M Goldenberg", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Lawrence A Leiter", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Nathasha Dhingra", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Anna Slabiak", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Kim A Connelly", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Andrew Liuni", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Biswajit Chowdhury", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["David H Fitchett", 2018, "EMPA-HEART Cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes \u2026"], ["Alain Combes", 2018, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a \u2026"], ["Daniel Brodie", 2018, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a \u2026"], ["Ewan C Goligher", 2018, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a \u2026"], ["Duminda N Wijeysundera", 2018, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a \u2026"], ["Eddy Fan", 2018, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a \u2026"], ["George Tomlinson", 2018, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a \u2026"], ["Arthur S Slutsky", 2018, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a \u2026"], ["David Hajage", 2018, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a \u2026"], ["Franz-Josef Neumann", 2018, "\u2018Ten commandments\u2019 for the 2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Paul Maranian", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Jan Moreb", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Sriram Ambadapadi", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Jiangwei Yao", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Jovil Kannampuzha", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Chintan Shah", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Stacey Schultz-Cherry", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Carl Pepine", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Alexandra Lucas", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Jordan Yaron", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Yan Gong", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Arvind Varsani", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Liqiang Zhang", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Melanie House", 2018, "Identification of viral gene signatures in cancer patients with reduced ejection fraction after chemotherapy"], ["Cornelia M Borkhoff", 2018, "Non-Technical Skills for Surgeons (NOTSS): Critical appraisal of its measurement properties"], ["Teodor P Grantcharov", 2018, "Non-Technical Skills for Surgeons (NOTSS): Critical appraisal of its measurement properties"], ["Takeshi Nishi", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Nikola Jagic", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["William F Fearon", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Sven M\u00f6bius-Winkler", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Pim Tonino", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Zsolt Piroth", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Fran\u00e7ois Derimay", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Emanuele Barbato", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Yuhei Kobayashi", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Nico HJ Pijls", 2018, "Fractional flow reserve and quality-of-life improvement after percutaneous coronary intervention in patients with stable coronary artery disease"], ["Hance Clarke", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Faraj W Abdallah", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Nasir Hussain", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Ian Gilron", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Uma Shastri", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Roger B Fillingim", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Joel Katz", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Duminda Wijeysundera", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Colin JL McCartney", 2018, "Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations"], ["Fran\u00e7ois Lellouche", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Kevin Thorpe", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Shay McGuinness", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Boris Khanykin", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Fran\u00e7ois M Carrier", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Alexander J Gregory", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Colin Royse", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Nikhil Mistry", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Alistair Royse", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Sean M Bagshaw", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Chirag Mehta", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Manfred D Seeberger", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Paul J Young", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Gregory MT Hare", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Stephen Fremes", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["David Dai", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Richard P Whitlock", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Nian-Chih Hwang", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Judith Hall", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Hilary P Grocott", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Summer Syed", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Dean A Fergusson", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Katherine Connolly", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Kelly Byrne", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Nadine Shehata", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Thomas W Painter", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Juan C Villar", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["\u00c9tienne de M\u00e9dicis", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Emilie Belley-Cote", 2018, "Six-month outcomes after restrictive or liberal transfusion for cardiac surgery"], ["Volker Sch\u00e4chinger", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Adam M\u0142odziankowski", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Pawel Buszman", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Pierre Lantelme", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Felice Gragnano", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Cokky van Meijeren", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Georg Delle Karth", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Florian Krackhardt", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Vasco Gama Ribeiro", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Ana Guimar\u00e3es", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["J\u00f3zsef Faluk\u00f6zy", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Martin Muurling", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Olivier Bertrand", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Edgard Freitas Quintella", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Jean-Fran\u00e7ois Morelle", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Ian Buysschaert", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Iv\u00e1n Horv\u00e1th", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Helge M\u00f6llman", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Jose Francisco Diaz", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Michael Angioi", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Philippe Brunel", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Rick Andreae", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Christopher Raffel", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Kurt Huber", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Coby Bouwman", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Dorien Hillen", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Guy Friedrich", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Negar Manavifar", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Didier Carrie", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Pawel Jasionowicz", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Antonio Serra Pe\u00f1aranda", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Eugene McFadden", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Nick Curzen", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Farzin Fath-Ordoubadi", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Eugene P McFadden", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Sylvain Plante", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Karim Ibrahim", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Sergio Leandro", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Helge M\u00f6llmann", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Yuki Katagiri", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Karl Isaaz", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Judith Jonk", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Carlos Collet", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Edouard Benit", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Istv\u00e1n \u00c9des", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Luc Janssens", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Ton Slagboom", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Tim Seidler", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Bela Merkely", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Leonardo Bolognese", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Manel Sabate", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Agustin Albarran Gonzalez-Trevilla", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Boudijn Ladan", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Taku Asano", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Marco Bressers", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Tone de Vreede", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Pedro Alves Lemos Neto", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Salvatore Curello", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Michael Magro", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Yosuke Miyazaki", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Adel Aminian", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Lynn Dijksma", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Paul Ong", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Farzin Beygui", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Ingo Eitel", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Werner Jung", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Carlos Macaya Miguel", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Grzegorz Galuszka", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Wietze Lindeboom", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Mariana Konteva", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Laura Mauri", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Christoph Liebetrau", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Gerrit Anne van Es", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Mohamed Abdellaoui", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Maurizio Ferrario", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Giuseppe Gargiulo", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Pascal Barraud", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Ina Hoekman", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Sanne Palsrok", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Geza Fontos", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Manuel Almeida", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Javier Goicolea", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Art Ghandilyan", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Aleksander Zurakowski", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Robert Jan Van Geuns", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Michael Munndt Ottesen", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Michael Haude", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Zolt\u00e1n Jambrik", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Gregor Leibundgut", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Annemarie Hugense", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Valeri Gelev", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Lene Holmvang", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Benno Rensing", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["David Hildick-Smith", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Christoph Kurt Naber", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["David Adlam", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Ivo Petrov", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Pieter Heijke", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Rosa Ana Hern\u00e1ndez Antolin", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Yvonne Kreuger", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Judith de Bot", 2018, "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy \u2026"], ["Haitham Ballo", 2018, "The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease \u2026"], ["Juhani Knuuti", 2018, "The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease \u2026"], ["Anne Wilhelmina Saskia Rutjes", 2018, "The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease \u2026"], ["Luis Eduardo Juarez-Orozco", 2018, "The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease \u2026"], ["Antti Saraste", 2018, "The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease \u2026"], ["Philippe Kolh", 2018, "The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease \u2026"], ["William Wijns", 2018, "The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease \u2026"], ["Joan Antoni G\u00f3mez Hospital", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Salvatore Colangelo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Paolo Sganzerla", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Rosario Evola", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Simone Tresoldi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Enrico Frigoli", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Pietro Vandoni", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Elmir Omerovic", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Antonio Micari", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Bernardo Cortese", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Jos\u00e9 Francisco D\u00edaz Fern\u00e1ndez", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Ugo Limbruno", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Marco Nazzaro", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Giampaolo Pasquetto", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Ezio Bramucci", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Roberto Bonmassari", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Gianluca Campo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Stefano Mameli", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Emilio Di Lorenzo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Andrea Santarelli", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Filippo Russo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Evelyn Regar", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Nicolas Van Mieghem", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Matteo Tebaldi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Carlo Briguori", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Carlo Penzo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Giacomo Boccuzzi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Gabriele Gabrielli", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Salvatore Ierna", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Edoardo Pucci", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Alessandro Lupi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Raffaele De Caterina", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Gennaro Sardella", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Sergio Leonardi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Paolo Rubartelli", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Dionigi Fischetti", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Armando Liso", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Vincenzo Guiducci", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Flavia Belloni", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Francesco Saia", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Paolo Tosi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Andrea Picchi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Giuseppe And\u00f3", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Fabio Ferrari", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Corrado Tamburino", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Marcello Caputo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Isala Klinieken", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Stefano Rigattieri", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Pietro Mazzarotto", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Marco Comeglio", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Fabio Abate", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Patrizia Presbitero", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Jose Maria de la Torre Hernandez", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Francesco Liistro", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Martina Rothenb\u00fchler", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Ciro Mauro", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Lucia Uguccioni", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Stefano De Servi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Anna Sonia Petronio", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Marco Contarini", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Arturo Ausiello", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Manuela Creaco", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Tiziana Zaro", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Roberto Violini", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Maurizio Turturo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Alaide Chieffo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Roberto Diletti", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Paolo Calabr\u00f2", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Dennis Zavalloni-Parenti", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Carlo Vigna", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Alessandro Sciahbasi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Stefano Garducci", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Claudio Moretti", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Alberto Cremonesi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Gavino Casu", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Claudio Fresco", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Francesco Amico", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Fabio Tarantino", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Camillo Falcone", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Giovanni Esposito", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Roberto Ceravolo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Salvatore Brugaletta", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Enrico Romagnoli", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Andrea Gagnor", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Arnoud van't Hof", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Giuseppe Ferrante", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Luciano Moretti", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Ferdinando Varbella", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Bruno Loi", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Roberto Garbo", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Antonio Zingarelli", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Giovanni Saccone", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Nicoletta de Cesare", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Andrea Perkan", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Marco Zimmarino", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Maria Letizia Stochino", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Vicente Mainar", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Antonio Dellavalle", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Cataldo Palmieri", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Fabio Mangiacapra", 2018, "Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a \u2026"], ["Susanna Price", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Renata Cifkova", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Tommaso Simoncini", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Mark Richard Johnson", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Michele De Bonis", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Ulrich Kintscher", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Petronella G Pieper", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Ute Seeland", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Lorna Swan", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Joao Morais", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Johann Bauersachs", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Giuseppe MC Rosano", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Irene Marthe Lang", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Vera Regitz-Zagrosek", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Jolien W Roos-Hesselink", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Peter Kranke", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Carole A Warnes", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Bernard Iung", 2018, "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the \u2026"], ["Marie-Annick Clavel", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Philippe Pibarot", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Bobby Yanagawa", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Josep Rod\u00e9s-Cabau", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Nancy Cot\u00e9", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Patrick Mathieu", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Nicolas Girerd", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Fran\u00e7ois Dagenais", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Dimitri Kalavrouziotis", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Siamak Mohammadi", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Rishi Puri", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Ha\u00effa Mahjoub", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Pierre Voisine", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["Erwan Salaun", 2018, "Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement"], ["David T Felson", 2018, "Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial"], ["Sarah Heldner", 2018, "Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial"], ["Armando Lenz", 2018, "Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial"], ["Stephan Reichenbach", 2018, "Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial"], ["Lukas Hunziker", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["St\u00e9phane Cook", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["Igal Moarof", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["George CM Siontis", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["Raffaele Piccolo", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["Christoph Kaiser", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["Franz R Eberli", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["Daniel Weilenmann", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["David T\u00fcller", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["Florim Cuculi", 2018, "Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5 \u2026"], ["Reinhold Kreutz", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Richard McManus", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Roland E Schmieder", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Stephane Laurent", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Enrico Agabiti Rosei", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Costas Tsioufis", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Thomas Kahan", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Evgeny Shlyakhto", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Bryan Williams", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Luis Ruilope", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Anna Dominiczak", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Giovanni De Simone", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Michel Burnier", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Giuseppe Mancia", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Wilko Spiering", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Josep Redon", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Alberto Zanchetti", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Ileana Desormais", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Michel Azizi", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Frank Ruschitzka", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Felix Mahfoud", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Antonio Coca", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Mary Kerins", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Sverre E Kjeldsen", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Gregory YH Lip", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Denis L Clement", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Krzysztof Narkiewicz", 2018, "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and \u2026"], ["Arnold von Eckardstein", 2018, "Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["Nicolas Rodondi", 2018, "Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["Nadine Sch\u00e4rer", 2018, "Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["Soheila Aghlmandi", 2018, "Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["Marcel Zwahlen", 2018, "Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["Sacha I Rothschild", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Richard Cathomas", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Christian Fankhauser", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Walter Mingrone", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Natalie Fischer", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Roman Inauen", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Alan Haynes", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Bettina Seifert", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Angelika Terbuch", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Christian Rothermundt", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Katrin Ziegler", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Anita Hirschi-Blickenstorfer", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Silke Gillessen", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Claudio Thurneisen", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Beat M\u00fcller", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Tobias Wehrhahn", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["J\u00f6rn Kamradt", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Thomas Kunit", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Thomas Grassmugg", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Christian Ruf", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Regina Woelky", 2018, "Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)."], ["Robert A Byrne", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Umberto Benedetto", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Josef Niebauer", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Anders Ahlsson", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Adnan Kastrati", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Volkmar Falk", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Giulio G Stefanini", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Rashmi Yadav", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Michael O Zembala", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Jean-Philippe Collet", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Adrian P Banning", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Steen D Kristensen", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Fernando Alfonso", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Akos Koller", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Dirk Sibbing", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Stuart J Head", 2018, "2018 ESC/EACTS Guidelines on myocardial revascularization"], ["Davide Capodanno", 2018, "Evaluating the importance of sham-controlled trials in the investigation of medical devices in interventional cardiology."], ["Andreas Baumbach", 2018, "Evaluating the importance of sham-controlled trials in the investigation of medical devices in interventional cardiology."], ["Jean Fajadet", 2018, "Evaluating the importance of sham-controlled trials in the investigation of medical devices in interventional cardiology."], ["I Colaiori", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["NHJ Pijls", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["P Tonino", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["WF Fearon", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["E Barbato", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["F Zimmermann", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["S Fournier", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["P Juni", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["B De Bruyne", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["M Pellicano", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["G Di Gioia", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["P Xaplanteris", 2018, "Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia"], ["Serge Zaugg", 2018, "A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation \u2026"], ["David J Kurz", 2018, "A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation \u2026"], ["Juan F Iglesias", 2018, "A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation \u2026"], ["Maxime Tapponnier", 2018, "A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation \u2026"], ["Andr\u00e9 Vuilliomenet", 2018, "A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation \u2026"], ["Petr Kala", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Habib Samady", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Thomas Engstr\u00f8m", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Kreton Mavromatis", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Anand Irimpen", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Nicola Jagic", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Gilles Rioufol", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Gabor G Toth", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Stefan K\u00e4\u00e4b", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Axel Linke", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Martin Mates", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Pim AL Tonino", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Ole Fr\u00f6bert", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Jan-Henk Dambrink", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Panagiotis Xaplanteris", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["Nils Witt", 2018, "Five-year outcomes with PCI guided by fractional flow reserve"], ["A Lenz", 2018, "LB0002 Biomechanical therapy for osteoarthritis of the knee: a randomised controlled trial (BIOTOK)"], ["S Heldner", 2018, "LB0002 Biomechanical therapy for osteoarthritis of the knee: a randomised controlled trial (BIOTOK)"], ["D Felson", 2018, "LB0002 Biomechanical therapy for osteoarthritis of the knee: a randomised controlled trial (BIOTOK)"], ["S Reichenbach", 2018, "LB0002 Biomechanical therapy for osteoarthritis of the knee: a randomised controlled trial (BIOTOK)"], ["Vincent Probst", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Michele Brignole", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Richard Sutton", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Perry M Elliott", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Matthew J Reed", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Frederik J de Lange", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Ciara P Rice", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Jean-Claude Deharo", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Alessandra Fanciulli", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Raffaello Furlan", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Andrea Ungar", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["J Gert van Dijk", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Alfonso Mart\u00edn", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Rose Anne Kenny", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Angel Moya", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Artur Fedorowski", 2018, "2018 ESC Guidelines for the diagnosis and management of syncope"], ["Michael Joner", 2018, "Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary"], ["Javier Escaned", 2018, "Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary"], ["Stefan James", 2018, "Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary"], ["Semih Oktay", 2018, "Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary"], ["Julia R Sharp", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Gordon Arbess", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Bryan Boodhoo", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Charmaine Camacho", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Lauren Kitney", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Julia Morinis", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Grace Jieun Lee", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Karen Eny", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sharon Naymark", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Anne Wormsbecker", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Gary Bloch", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sylvie Bergeron", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Maya Nader", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Jennifer Bugera", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Eliana M Perrin", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Anne Brown", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Thea Weisdorf", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Tony Barozzino", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Shannon Weir", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Barbara Smiltnieks", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Mary Beth Derocher", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Peter Szatmari", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Weeda Zabih", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Julia Thompson", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sheila Lakhoo", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Noor Ramji", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Michael Zajdman", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Caroline Calpin", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sharon Gazeley", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sarah Mahmoud", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Christine Kowal", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Kawsari Abdullah", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Tarandeep Malhi", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Jessica Omand", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Nasreen Ramji", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Anne Egger", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Eddy Lau", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Andrew Pinto", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Tracy Pitt", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Gwen Jansz", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Suzanne Turner", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Michael Salter", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sheila Wijayasinghe", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Marty Perlmutar", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Jodi Shim", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Paul Das", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Kifi Pena", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Jillian Baker", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Thivia Jegathesan", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["James Owen", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Susan Shepherd", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sohail Cheema", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sheila Jacobson", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Peter Wong", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Patricia Li", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Michael Peer", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Hailey Hatch", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Alan Li", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Cinntha Srikanthan", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["David WH Dai", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Imaan Bayoumi", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Shuja Hafiz", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Tara Kiran", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Kathleen Doukas", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Joanne Louis", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Ethel Ying", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Marivic Bustos", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Christine Koroshegyi", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Karen Pope", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Michael Sgro", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Cindy-Lee Dennis", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Christopher Allen", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Elizabeth Young", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Nicholas Blanchette", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Erin Culbert", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Donna Goldenberg", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sloane Freeman", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Shiyi Chen", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Denise Darmawikarta", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Laura Hanson", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Azar Azad", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Patricia C Parkin", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Carolyn Taylor", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sarah Carsley", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Dimple Bhagat", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Holly Knowles", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Kayla Furlong", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Dalah Mason", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Margarita Lam-Antoniades", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Jane Parry", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Elaine Cheng", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Roy Male", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Evelyn Constantin", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Shelley Vanderhout", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Anh Do", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Fok-Han Leung", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Ashna Bowry", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Karoon Danayan", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Yamna Ali", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Murtala Abdurrahman", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Vanna Schiralli", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Jennifer Loo", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Katherine Rouleau", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Meta van den Heuvel", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Janet Saunderson", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Dharma Dalwadi", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Vashti Mascoll", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Laura N Anderson", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Paul Kadar", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Kelly Anderson", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Charlie Guiang", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Barbara Anderson", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Brian Chisamore", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Amy Freedman", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Joanne Vaughan", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Kanthi Kavikondala", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Michael Dorey", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Laurie Thompson", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Yang Chen", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Lesley Plumptre", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Allison Farber", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Sharon Thadani", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Stephanie Erdle", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Leah Harrington", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Bruce Kwok", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Patricia Neelands", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Fatima Uddin", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Dan Ha", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Lukasz Jagiello", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Rahul Saxena", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Douglas Campbell", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Teresa Hughes", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Michelle Porepa", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Curtis Handford", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Vikky Qi", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Joey Bonifacio", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Keewai Fung", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Rosemary Moodie", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Jesleen Rana", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Alana Rosenthal", 2018, "Temperament Is Associated With Outdoor Free Play in Young Children: A TARGet Kids! Study"], ["Stephen Spindel", 2018, "Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis: A Systematic Review and Meta-analysis"], ["John D Puskas", 2018, "Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis: A Systematic Review and Meta-analysis"], ["Derrick Y Tam", 2018, "Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis: A Systematic Review and Meta-analysis"], ["Amine Mazine", 2018, "Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis: A Systematic Review and Meta-analysis"], ["Jan O Friedrich", 2018, "Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis: A Systematic Review and Meta-analysis"], ["Lukas B\u00fctikofer", 2018, "Predicting drug efficacy in chronic low back pain by quantitative sensory tests"], ["P Vuilleumier", 2018, "Predicting drug efficacy in chronic low back pain by quantitative sensory tests"], ["Ulrike Stamer", 2018, "Predicting drug efficacy in chronic low back pain by quantitative sensory tests"], ["Lars Arendt\u2010Nielsen", 2018, "Predicting drug efficacy in chronic low back pain by quantitative sensory tests"], ["A Siegenthaler", 2018, "Predicting drug efficacy in chronic low back pain by quantitative sensory tests"], ["Michele Curatolo", 2018, "Predicting drug efficacy in chronic low back pain by quantitative sensory tests"], ["J\u00fcrg Schliessbach", 2018, "Predicting drug efficacy in chronic low back pain by quantitative sensory tests"], ["Jozef Bartunek", 2018, "Angiography versus hemodynamics to predict the natural history of coronary stenoses: fractional flow reserve versus angiography in multivessel evaluation 2 substudy"], ["Marc Vanderheyden", 2018, "Angiography versus hemodynamics to predict the natural history of coronary stenoses: fractional flow reserve versus angiography in multivessel evaluation 2 substudy"], ["Anastasios Milkas", 2018, "Angiography versus hemodynamics to predict the natural history of coronary stenoses: fractional flow reserve versus angiography in multivessel evaluation 2 substudy"], ["Brigitta Gahl", 2018, "Angiography versus hemodynamics to predict the natural history of coronary stenoses: fractional flow reserve versus angiography in multivessel evaluation 2 substudy"], ["Giovanni Ciccarelli", 2018, "Angiography versus hemodynamics to predict the natural history of coronary stenoses: fractional flow reserve versus angiography in multivessel evaluation 2 substudy"], ["Nico Pijls", 2018, "Angiography versus hemodynamics to predict the natural history of coronary stenoses: fractional flow reserve versus angiography in multivessel evaluation 2 substudy"], ["Helmut Baumgartner", 2018, "The 2017 ESC/EACTS guidelines on the management of valvular heart disease"], ["Sebastian Debus", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Serge Kownator", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Marianne Brodmann", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Marie-Louise EL Bartelink", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Martin Czerny", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Lucia Mazzolai", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Maarit Venermo", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Jean-Baptiste Ricco", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Marco De Carlo", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Gunnar Tepe", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Christine Espinola-Klein", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Joachim Roether", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["A Ross Naylor", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Charalambos Vlachopoulos", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Tina Cohnert", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Michal Tendera", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Muriel Sprynger", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Martin Bj\u00f6rck", 2018, "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering \u2026"], ["Ayodele Odutayo", 2018, "Prognostic value of early postoperative troponin T in patients undergoing coronary artery bypass grafting"], ["Hendrik T Tevaearai Stahel", 2018, "Prognostic value of early postoperative troponin T in patients undergoing coronary artery bypass grafting"], ["Volkhard G\u00f6ber", 2018, "Prognostic value of early postoperative troponin T in patients undergoing coronary artery bypass grafting"], ["Olivia Chan", 2018, "Prognostic value of early postoperative troponin T in patients undergoing coronary artery bypass grafting"], ["G Martin Fiedler", 2018, "Prognostic value of early postoperative troponin T in patients undergoing coronary artery bypass grafting"], ["Stephan M Jakob", 2018, "Prognostic value of early postoperative troponin T in patients undergoing coronary artery bypass grafting"], ["Thierry P Carrel", 2018, "Prognostic value of early postoperative troponin T in patients undergoing coronary artery bypass grafting"], ["Georgia Salanti", 2018, "Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials"], ["Bernadette Coles", 2018, "Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials"], ["Dimitris Mavridis", 2018, "Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials"], ["Adriani Nikolakopoulou", 2018, "Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials"], ["John P Greenwood", 2018, "Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials"], ["Christoph Agten", 2018, "Relationship of Radiographic Osteoarthritis Severity with Treatment Outcomes after Imaging-Guided Knee Injections: A Prospective Outcomes Study"], ["Christian Pfirrmann", 2018, "Relationship of Radiographic Osteoarthritis Severity with Treatment Outcomes after Imaging-Guided Knee Injections: A Prospective Outcomes Study"], ["Cynthia Peterson", 2018, "Relationship of Radiographic Osteoarthritis Severity with Treatment Outcomes after Imaging-Guided Knee Injections: A Prospective Outcomes Study"], ["Reto Sutter", 2018, "Relationship of Radiographic Osteoarthritis Severity with Treatment Outcomes after Imaging-Guided Knee Injections: A Prospective Outcomes Study"], ["Ivan Miletic", 2018, "Relationship of Radiographic Osteoarthritis Severity with Treatment Outcomes after Imaging-Guided Knee Injections: A Prospective Outcomes Study"], ["Mark A Hlatky", 2018, "Clinical outcomes and cost-effectiveness of fractional flow reserve\u2013guided percutaneous coronary intervention in patients with stable coronary artery disease: three-year follow \u2026"], ["Derek B Boothroyd", 2018, "Clinical outcomes and cost-effectiveness of fractional flow reserve\u2013guided percutaneous coronary intervention in patients with stable coronary artery disease: three-year follow \u2026"], ["Francesco Costa", 2018, "Case-based implementation of the 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease"], ["Gilles Montalescot", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["Jose Luis Zamorano", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["Anders Jeppsson", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["Glenn N Levine", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["H\u00e9ctor Bueno", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["Mate Petricevic", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["U Sechtem", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["JP Collet", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["A Kastrati", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["L Pierard", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["S James", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["MS Uva", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["PG Steg", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["F Verheugt", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["S Windecker", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["O Gaemperli", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["European Association for Cardio-Thoracic Surgery (EACTS", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["MF Lip G Piepoli", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["A Jeppsson", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["FJ Neumann", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["M Gilard", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["M Tendera", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["M Lettino", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["M Roffi", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["JP Bassand", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["B Ibanez", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["IA Simpson", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["H Bueno", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["E Antman", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["M Schwerzmann", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["N Galie", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["L Mauri", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["JL Zamorano", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["M Cikirikcioglu", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["M Petricevic", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["J Knuuti", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["B Lung", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["CW Hamm", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["G Montalescot", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["P Kolh", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["F Andreotti", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["D Fitzsimons", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["F Costa", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["E Stabile", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["T Cuisset", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["S Agewall", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["C Leclercq", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["U Landmesser", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["R Bugiardini", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["M De Bonis", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["V Delgado", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["RF Storey", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["RA Byrne", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["F Van deWerf", 2018, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"], ["Jean-philippe Collet", 2018, "Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment \u2026"], ["Martin Bjo", 2018, "Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment \u2026"], ["Martin Czerny Germany", 2018, "Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment \u2026"], ["A Uk", 2018, "Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment \u2026"], ["Michal Tendera Poland", 2018, "Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment \u2026"], ["Jos\u00e9 Luis Zamorano", 2018, "Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS."], ["Susanne Zwahlen", 2018, "A Structured Early Palliative Care Intervention for Patients with Advanced Cancer-A Randomized Controlled Trial"], ["Martin Fey", 2018, "A Structured Early Palliative Care Intervention for Patients with Advanced Cancer-A Randomized Controlled Trial"], ["Sven Trelle", 2018, "A Structured Early Palliative Care Intervention for Patients with Advanced Cancer-A Randomized Controlled Trial"], ["Monica Fliedner", 2018, "A Structured Early Palliative Care Intervention for Patients with Advanced Cancer-A Randomized Controlled Trial"], ["Maud Maessen", 2018, "A Structured Early Palliative Care Intervention for Patients with Advanced Cancer-A Randomized Controlled Trial"], ["Daniel Aebersold", 2018, "A Structured Early Palliative Care Intervention for Patients with Advanced Cancer-A Randomized Controlled Trial"], ["Steffen Eychm\u00fcller", 2018, "A Structured Early Palliative Care Intervention for Patients with Advanced Cancer-A Randomized Controlled Trial"], ["Drahomir Aujesky", 2018, "A Structured Early Palliative Care Intervention for Patients with Advanced Cancer-A Randomized Controlled Trial"], ["Ellen Culbert", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["Ian Zenlea", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["Megan Smith", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["Jonathan L Maguire", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["Hafiz Shuja", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["Arthana Chandraraj", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["Peter D Wong", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["Ayesha Islam", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["David DW Dai", 2018, "The association of breastfeeding duration and early childhood cardiometabolic risk"], ["Andreas Limacher", 2018, "Effect of single-dose imipramine on chronic low-back and experimental pain: A randomized controlled trial"], ["Pascal H Vuilleumier", 2018, "Effect of single-dose imipramine on chronic low-back and experimental pain: A randomized controlled trial"], ["Lars Arendt-Nielsen", 2018, "Effect of single-dose imipramine on chronic low-back and experimental pain: A randomized controlled trial"], ["Andreas Siegenthaler", 2018, "Effect of single-dose imipramine on chronic low-back and experimental pain: A randomized controlled trial"], ["M Rothenb\u00fchler", 2018, "Five-Year Outcomes with PCI Guided by Fractional Flow Reserve"], ["A Irimpen", 2018, "Five-Year Outcomes with PCI Guided by Fractional Flow Reserve"], ["K Oldroyd", 2018, "Five-Year Outcomes with PCI Guided by Fractional Flow Reserve"], ["G Campo", 2018, "Five-Year Outcomes with PCI Guided by Fractional Flow Reserve"], ["Fabian Nietlispach", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["James Adams", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["Thomas Gilhofer", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["Antonio H Frangieh", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["Christian Templin", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["Kyohei Yamaji", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["Yannik Bockhorn", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["Nooraldaem Yousif", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["Milosz Jaguszewski", 2018, "Prognostic value of SYNTAX score II in patients with acute coronary syndromes referred for invasive management: a subanalysis from the SPUM and COMFORTABLE AMI cohorts"], ["Sacha Rothschild", 2018, "Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)"], ["Natalie Fischer Fischer", 2018, "Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)"], ["Christian Daniel Fankhauser", 2018, "Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)"], ["Claudio Thurneysen", 2018, "Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)"], ["Emmanuel Lansac", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Thomas Walther", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Daniel Rodriguez Munoz", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Olaf Wendler", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Johan Sj\u00f6gren", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Pilar Tornos Mas", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Raphael Rosenhek", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Patrizio Lancellotti", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Alec Vahanian", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Per Johan Holm", 2018, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Sigrun Halvorsen", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["John A Goudevenos", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Chiara Bucciarelli-Ducci", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Stefan Agewall", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Filippo Crea", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Manuel J Antunes", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Christoph Varenhorst", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Petr Widimsk\u00fd", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Eva Prescott", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Alida LP Caforio", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Mattie J Lenzen", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Borja Ibanez", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Gerhard Hindricks", 2018, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation"], ["Nikolay Pavlov", 2018, "Long-term oxygen therapy in COPD patients: population-based cohort study on mortality"], ["Sebastian Robert Ott", 2018, "Long-term oxygen therapy in COPD patients: population-based cohort study on mortality"], ["Armin Stucki", 2018, "Long-term oxygen therapy in COPD patients: population-based cohort study on mortality"], ["Alan Gary Haynes", 2018, "Long-term oxygen therapy in COPD patients: population-based cohort study on mortality"], ["E Salaun", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["B Yanagawa", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["MA Clavel", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["F Dagenais", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["D Kalavrouziotis", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["S Mohammadi", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["S Verma", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["P Pibarot", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["N Girerd", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["P Voisine", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["H Mahjoub", 2018, "Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement"], ["Rashmi Nedadur", 2018, "Systematic review and meta-analysis of chordal replacement versus leaflet resection for posterior mitral leaflet prolapse"], ["Maral Ouzounian", 2018, "Systematic review and meta-analysis of chordal replacement versus leaflet resection for posterior mitral leaflet prolapse"], ["Salvatore Cassese", 2018, "Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of \u2026"], ["Massimiliano Fusaro", 2018, "Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of \u2026"], ["Serban Puricel", 2018, "Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of \u2026"], ["Jose PS Henriques", 2018, "Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of \u2026"], ["Takeshi Kimura", 2018, "Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of \u2026"], ["Heribert Schunkert", 2018, "Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of \u2026"], ["Stephane Cook", 2018, "Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of \u2026"], ["Gjin Ndrepepa", 2018, "Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of \u2026"], ["Helena Marti Soler", 2017, "Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes"], ["Pedro-Manuel Marques-Vidal", 2017, "Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes"], ["Stefan Zoller", 2017, "Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes"], ["Chad Brokopp", 2017, "Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes"], ["Oliver D\u00f6rr", 2017, "Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes"], ["Alexander Akhmedov", 2017, "Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes"], ["Peter Vollenweider", 2017, "Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes"], ["Fabrizio Montecucco", 2017, "Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes"], ["Borja Ib\u00e1nez", 2017, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation."], ["Susan Armijo-Olivo", 2017, "Effect of standardized training on the reliability of the Cochrane risk of bias assessment tool: a prospective study"], ["Alison Diaz", 2017, "Effect of standardized training on the reliability of the Cochrane risk of bias assessment tool: a prospective study"], ["Nina M Resta", 2017, "Effect of standardized training on the reliability of the Cochrane risk of bias assessment tool: a prospective study"], ["Matthias Egger", 2017, "Effect of standardized training on the reliability of the Cochrane risk of bias assessment tool: a prospective study"], ["Bradley C Johnston", 2017, "Effect of standardized training on the reliability of the Cochrane risk of bias assessment tool: a prospective study"], ["Brooke Beckett", 2017, "Effect of standardized training on the reliability of the Cochrane risk of bias assessment tool: a prospective study"], ["Nian C Hwang", 2017, "Restrictive or liberal red-cell transfusion for cardiac surgery"], ["Ashley Cohen", 2017, "Restrictive or liberal red-cell transfusion for cardiac surgery"], ["Dimitris Kalavrouziotis", 2017, "Incidence, Predictors, and Impact of Bioprosthetic Valve Hemodynamic Deterioration Following Aortic Valve Replacement"], ["Francois Dagenais", 2017, "Incidence, Predictors, and Impact of Bioprosthetic Valve Hemodynamic Deterioration Following Aortic Valve Replacement"], ["Damian N Meli", 2017, "Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial"], ["Kathrin M\u00fchlemann", 2017, "Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial"], ["Andreas Kronenberg", 2017, "Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial"], ["Markus Battaglia", 2017, "Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial"], ["Peter Frey", 2017, "Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial"], ["Tetyana Kendzerska", 2017, "The longitudinal relationship between hand, hip and knee osteoarthritis and cardiovascular events: a population-based cohort study"], ["Lauren K King", 2017, "The longitudinal relationship between hand, hip and knee osteoarthritis and cardiovascular events: a population-based cohort study"], ["Gillian A Hawker", 2017, "The longitudinal relationship between hand, hip and knee osteoarthritis and cardiovascular events: a population-based cohort study"], ["Ian Stanaitis", 2017, "The longitudinal relationship between hand, hip and knee osteoarthritis and cardiovascular events: a population-based cohort study"], ["Ruth Croxford", 2017, "The longitudinal relationship between hand, hip and knee osteoarthritis and cardiovascular events: a population-based cohort study"], ["J Friedrich", 2017, "IMPACT OF TOTAL ARTERIAL REVASCULARIZATION ON LONG-TERM SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 130,305 PATIENTS"], ["J Puskas", 2017, "IMPACT OF TOTAL ARTERIAL REVASCULARIZATION ON LONG-TERM SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 130,305 PATIENTS"], ["A Mazine", 2017, "IMPACT OF TOTAL ARTERIAL REVASCULARIZATION ON LONG-TERM SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 130,305 PATIENTS"], ["D Tam", 2017, "IMPACT OF TOTAL ARTERIAL REVASCULARIZATION ON LONG-TERM SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 130,305 PATIENTS"], ["S Spindel", 2017, "HOMOGRAFT VERSUS CONVENTIONAL PROSTHESIS FOR SURGICAL MANAGEMENT OF AORTIC VALVE INFECTIVE ENDOCARDITIS A SYSTEMATIC REVIEW AND META-ANALYSIS"], ["D Bhatt", 2017, "HOMOGRAFT VERSUS CONVENTIONAL PROSTHESIS FOR SURGICAL MANAGEMENT OF AORTIC VALVE INFECTIVE ENDOCARDITIS A SYSTEMATIC REVIEW AND META-ANALYSIS"], ["Pascal Vuilleumier", 2017, "Quantitative sensory tests fairly reflect immediate effects of oxycodone in chronic low-back pain"], ["Vadim Shumavets", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Oliver Gaemperli", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Guy Van Camp", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Theresa McDonagh", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Hugo A Katus", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Christophe Leclercq", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Donna Fitzsimons", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Johan Sjogren", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Iain A Simpson", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Veronica Dean", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Daniela Loncar", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Daniela Lovric", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Katerina Linhartova", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Ioan Mircea Coman", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Piotr Ponikowski", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Julia Mascherbauer", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Fuad Samadov", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Massimo Francesco Piepoli", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Georgios M Georgiou", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Hector Bueno", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Hovhannes K Kzhdryan", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC \u2026"], ["Stefan Stortecky", 2017, "Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a study of age-and gender-matched cohorts"], ["Thomas Zanchin", 2017, "Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a study of age-and gender-matched cohorts"], ["Peter Wenaweser", 2017, "Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a study of age-and gender-matched cohorts"], ["Kostantinos Koskinas", 2017, "Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a study of age-and gender-matched cohorts"], ["Masahiko Asami", 2017, "Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a study of age-and gender-matched cohorts"], ["Anna Franzone", 2017, "Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a study of age-and gender-matched cohorts"], ["Jonas Lanz", 2017, "Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a study of age-and gender-matched cohorts"], ["Fabien Praz", 2017, "Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a study of age-and gender-matched cohorts"], ["Ole K\u00e6seler Andersen", 2017, "Measurement error of a simplified protocol for quantitative sensory tests in chronic pain patients"], ["Jos\u00e9 Alberto Biurrun Manresa", 2017, "Measurement error of a simplified protocol for quantitative sensory tests in chronic pain patients"], ["Monika M\u00fcller", 2017, "Measurement error of a simplified protocol for quantitative sensory tests in chronic pain patients"], ["Konrad Streitberger", 2017, "Measurement error of a simplified protocol for quantitative sensory tests in chronic pain patients"], ["Pascal Henri Vuilleumier", 2017, "Analgesic effect of clobazam in chronic low\u2010back pain but not in experimentally induced pain"], ["Hanns U Zeilhofer", 2017, "Analgesic effect of clobazam in chronic low\u2010back pain but not in experimentally induced pain"], ["Daniel Rodriguez Mu\u00f1oz", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["Authors/Task Force Members:", 2017, "2017 ESC/EACTS Guidelines for the management of valvular heart disease"], ["D Heg", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["R Klingenberg", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["B Gencer", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["S Aghlmandi", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["N Rodondi", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["D Nanchen", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["CM Matter", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["P Jueni", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["D Carballo", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["A Von Eckardstein", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["F Mach", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["TF Luescher", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["L Raeber", 2017, "Thrombus aspiration in acute coronary syndromes: Prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort"], ["David C Goodman", 2017, "Caesarean sections and private insurance: systematic review and meta-analysis"], ["Ilir Hoxha", 2017, "Caesarean sections and private insurance: systematic review and meta-analysis"], ["Lamprini Syrogiannouli", 2017, "Caesarean sections and private insurance: systematic review and meta-analysis"], ["Medina Braha", 2017, "Caesarean sections and private insurance: systematic review and meta-analysis"], ["Adam Witkowski", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["David P Taggart", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["G\u00fcnther Laufer", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["Lucia Torracca", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["Berend Beumer", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["Patrick Schauerte", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["Jochen Cremer", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["A Pieter Kappetein", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["Peter M Clemmensen", 2017, "Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis"], ["Eva Roost", 2017, "Rates and predictors of hospital readmission after transcatheter aortic valve implantation"], ["Bettina Langhammer", 2017, "Rates and predictors of hospital readmission after transcatheter aortic valve implantation"], ["Thierry Carrel", 2017, "Rates and predictors of hospital readmission after transcatheter aortic valve implantation"], ["Nicolas Arnold", 2017, "Rates and predictors of hospital readmission after transcatheter aortic valve implantation"], ["Simon Wandel", 2017, "Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis"], ["Linda Nartey", 2017, "Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis"], ["Noah Keller", 2017, "Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis"], ["Suleyman Tas", 2017, "A single-center prospective observational study of ultrasonography for 6 months after surgical decompression of the median nerve at the carpal tunnel"], ["Gerhard Marquardt", 2017, "A single-center prospective observational study of ultrasonography for 6 months after surgical decompression of the median nerve at the carpal tunnel"], ["Stephan Duetzmann", 2017, "A single-center prospective observational study of ultrasonography for 6 months after surgical decompression of the median nerve at the carpal tunnel"], ["Frank Staub", 2017, "A single-center prospective observational study of ultrasonography for 6 months after surgical decompression of the median nerve at the carpal tunnel"], ["Christian Senft", 2017, "A single-center prospective observational study of ultrasonography for 6 months after surgical decompression of the median nerve at the carpal tunnel"], ["Volker Seifert", 2017, "A single-center prospective observational study of ultrasonography for 6 months after surgical decompression of the median nerve at the carpal tunnel"], ["Thomas Dombert", 2017, "A single-center prospective observational study of ultrasonography for 6 months after surgical decompression of the median nerve at the carpal tunnel"], ["Ferdinando Priano", 2017, "Early efficacy of intra-articular HYADD\u00ae 4 (Hymovis\u00ae) injections for symptomatic knee osteoarthritis"], ["Vinay Garg", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["F Victor Chu", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Natasha Dhingra", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Thomas R Marotta", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Mark D Peterson", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Roderick GG MacArthur", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Ankit Garg", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["John Bozinovski", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Muhammad Mamdani", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["David A Latter", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Michael WA Chu", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Ismail El-Hamamsy", 2017, "Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 \u2026"], ["Fernando Varbella", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Tiziana Coco", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Eva Michalska", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Monia Monti", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Monica Portolan", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Gabriella Visconti", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Lorenzo Cagliari", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Nestor Ciociano", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Maria Salomone", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Elena Guerra", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Sara Ariotti", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Mario Galli", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Erika Delos", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Marcello Marino", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Vincenzo Serino", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Sunil V Rao", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Sara Castellini", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Marco Anzini", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Gianluca Pendenza", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Pierluigi Tricoci", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Davide Gazzotti", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Linda Valli", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Elisa Silvetti", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Leila Shahmohammadi", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Vittorio Virga", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Maria Grazia Mazzone", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Arnoud WJ van\u2018t Hof", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Stefano Tresoldi", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Pierpaolo Occhilupo", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["MATRIX Investigators", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Marianna Adamo", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Giuseppe And\u00f2", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Maria Teresa Caruso", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Veronica Lodolini", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Martina Caiazza", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Maggie Testa", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Maurizio Lazzero", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Nunzio Russo", 2017, "Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX"], ["Paolo Calabria", 2017, "Radiation exposure and vascular access in acute coronary syndromes: the RAD-Matrix trial"], ["Dennis Zavalloni", 2017, "Radiation exposure and vascular access in acute coronary syndromes: the RAD-Matrix trial"], ["Francesco Tomassini", 2017, "Radiation exposure and vascular access in acute coronary syndromes: the RAD-Matrix trial"], ["Alessandro Sarandrea", 2017, "Radiation exposure and vascular access in acute coronary syndromes: the RAD-Matrix trial"], ["Enrico Cerrato", 2017, "Radiation exposure and vascular access in acute coronary syndromes: the RAD-Matrix trial"], ["Z Piroth", 2017, "A prospective natural history study of coronary atherosclerosis using fractional flow reserve"], ["G Toth-Gayor", 2017, "A prospective natural history study of coronary atherosclerosis using fractional flow reserve"], ["N Johnson", 2017, "A prospective natural history study of coronary atherosclerosis using fractional flow reserve"], ["W Fearon", 2017, "A prospective natural history study of coronary atherosclerosis using fractional flow reserve"], ["N Pijls", 2017, "A prospective natural history study of coronary atherosclerosis using fractional flow reserve"], ["Haroon Ahmad", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Steve Morgan", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Andrew Boozary", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Yathavan Rajakulasingam", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Michael Law", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Nav Persaud", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Michael Sergio Taglione", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Winny Li", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Paul Oh", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Braden Manns", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Taehoon Lee", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Frank M Sullivan", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Andrew David Pinto", 2017, "Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge \u2026"], ["Kwan-Leung Chan", 2017, "Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)"], ["Benoit E de Varennes", 2017, "Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)"], ["Thierry G Mesana", 2017, "Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)"], ["Wendy Tsang", 2017, "Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)"], ["Kibar Yared", 2017, "Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)"], ["Howard Leong-Poi", 2017, "Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)"], ["Marc Ruel", 2017, "Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)"], ["Vincent Chan", 2017, "Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)"], ["Shamini Murugavel", 2017, "Impact of total arterial revascularization on long term survival: a systematic review and meta-analysis of 130,305 patients"], ["Nicoletta Franco", 2017, "Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation"], ["Nicoletta De Cesare", 2017, "Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation"], ["Fabrizio Ugo", 2017, "Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation"], ["Anita Paggi", 2017, "Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation"], ["Georgios Siontis", 2017, "NON-INVASIVE FUNCTIONAL AND ANATOMICAL DIAGNOSTIC TESTING FOR PATIENTS WITH LOW-RISK ACUTE CORONARY SYNDROMES: A NETWORK META-ANALYSIS OF DIAGNOSTIC RANDOMIZED CONTROLLED TRIALS"], ["Konstantinos Siontis", 2017, "NON-INVASIVE FUNCTIONAL AND ANATOMICAL DIAGNOSTIC TESTING FOR PATIENTS WITH LOW-RISK ACUTE CORONARY SYNDROMES: A NETWORK META-ANALYSIS OF DIAGNOSTIC RANDOMIZED CONTROLLED TRIALS"], ["Ken Kozuma", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Kentaro Hayashida", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Motoharu Araki", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Shinichi Shirai", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Akihisa Kataoka", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Futoshi Yamanaka", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Yusuke Watanabe", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Masanori Yamamoto", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Yugo Nara", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Norio Tada", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Kensuke Takagi", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Hirofumi Hioki", 2017, "Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve."], ["Christopher Kaiser", 2017, "Impact of patient and lesion complexity on long-term outcomes following coronary revascularization with new-generation drug-eluting stents"], ["Fabio Rigamonti", 2017, "Impact of patient and lesion complexity on long-term outcomes following coronary revascularization with new-generation drug-eluting stents"], ["Masanori Taniwaki", 2017, "Impact of patient and lesion complexity on long-term outcomes following coronary revascularization with new-generation drug-eluting stents"], ["Peiman Jamshidi", 2017, "Impact of patient and lesion complexity on long-term outcomes following coronary revascularization with new-generation drug-eluting stents"], ["Andre Vuillomenet", 2017, "Impact of patient and lesion complexity on long-term outcomes following coronary revascularization with new-generation drug-eluting stents"], ["Mark Reisman", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["Anthony J Furlan", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["David E Thaler", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["Robin Ruthazer", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["David M Kent", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["Richard W Smalling", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["Jeffrey L Saver", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["Issa J Dahabreh", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["RoPE Investigators", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["Bernhard Meier", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["John D Carroll", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["Heinrich P Mattle", 2017, "Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure"], ["Xhyljeta Luta", 2017, "Caesarean sections and for-profit status of hospitals: systematic review and meta-analysis"], ["Kali Tal", 2017, "Caesarean sections and for-profit status of hospitals: systematic review and meta-analysis"], ["Laure Perrier", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["Mark Smith", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["Laura C Rosella", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["Merrick Zwarenstein", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["Tiffany Fitzpatrick", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["Lisa M Lix", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["David A Henry", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["Sharon E Straus", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["Andrea C Tricco", 2017, "Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data"], ["Dierik Hans Heg", 2017, "Selective use of contemporary drug eluting stents in primary angioplasty for ST elevation myocardial infarction. Pooled analysis of COMFORTABLE-AMI and EXAMINATION."], ["Julian W Strange", 2017, "Selective use of contemporary drug eluting stents in primary angioplasty for ST elevation myocardial infarction. Pooled analysis of COMFORTABLE-AMI and EXAMINATION."], ["Thomas W Johnson", 2017, "Selective use of contemporary drug eluting stents in primary angioplasty for ST elevation myocardial infarction. Pooled analysis of COMFORTABLE-AMI and EXAMINATION."], ["Miodrag Ostoijc", 2017, "Selective use of contemporary drug eluting stents in primary angioplasty for ST elevation myocardial infarction. Pooled analysis of COMFORTABLE-AMI and EXAMINATION."], ["M Dominici", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["PE Buszman", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["U Baber", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["V Valkov", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["J Prokopczuk", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["CC Chang", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["T Rademaker-Havinga", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["GLOBAL LEADERS Investigators", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["R Modolo", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["K \u017bmudka", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["E Spitzer", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["K Takahashi", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["PW Serruys", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["Y Onuma", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["M Sabate", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["C Hamm", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["R Anderson", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["M Valgimigli", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["JGP Tijssen", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["RJ van Geuns", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["T Geisler", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["P Chichareon", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["N Kogame", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["P Vranckx", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["C Steinwender", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["M Tomaniak", 2017, "Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD"], ["Mate Peticevic", 2017, "Uaktualnione stanowisko ESC dotyczace stosowania podwojnej terapii przeciwplytkowej w chorobie wiencowej w 2017 roku, przygotowane we wspolpracy z EACTS"], ["2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS", 2017, "The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery \u2026"], ["Eliane Rohner", 2017, "Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the \u2026"], ["Julia Bohlius", 2017, "Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the \u2026"], ["Michael Grabik", 2017, "Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the \u2026"], ["Thomy Tonia", 2017, "Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the \u2026"], ["Frank Petavy", 2017, "Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the \u2026"], ["Francesco Pignatti", 2017, "Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the \u2026"], ["Josepa Mauri Ferr\u00e9", 2017, "A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary \u2026"], ["Marie-Claude Morice", 2017, "A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary \u2026"], ["Ghada W Mikhail", 2017, "A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary \u2026"], ["Maria Grazia Modena", 2017, "A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary \u2026"], ["Liliana Grinfeld", 2017, "A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary \u2026"], ["Ruth Strasser", 2017, "A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary \u2026"], ["Goran K Olivecrona", 2017, "The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction"], ["Chee Tang Chin", 2017, "The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction"], ["Philippe L'Allier", 2017, "The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction"], ["Francesco Maisano", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["Christoph Huber", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["David Tueller", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["St\u00e9phane Laurent Noble", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["Stefan Toggweiler", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["Raban Jeger", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["Enrico Ferrari", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["Maurizio Taramasso", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["J\u00fcrg Gr\u00fcnenfelder", 2017, "Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis"], ["Roman Hari", 2016, "Intra-articular corticosteroids for osteoarthritis of the knee"], ["Lars S\u00f8ndergaard", 2016, "Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials"], ["Peter Martin Wenaweser", 2016, "Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction."], ["Ahmed Aziz Khattab", 2016, "Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction."], ["Stefan Bl\u00f6chlinger", 2016, "Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction."], ["Marinella Gugliotta", 2016, "Surgical versus conservative treatment for lumbar disc herniation: a prospective cohort study"], ["Essam Dabis", 2016, "Surgical versus conservative treatment for lumbar disc herniation: a prospective cohort study"], ["Robert Theiler", 2016, "Surgical versus conservative treatment for lumbar disc herniation: a prospective cohort study"], ["Paul Hasler", 2016, "Surgical versus conservative treatment for lumbar disc herniation: a prospective cohort study"], ["Hans Landolt", 2016, "Surgical versus conservative treatment for lumbar disc herniation: a prospective cohort study"], ["Fabienne Treichel", 2016, "Discriminative ability of reflex receptive fields to distinguish patients with acute and chronic low back pain"], ["Paul Heini", 2016, "Discriminative ability of reflex receptive fields to distinguish patients with acute and chronic low back pain"], ["Ole K Andersen", 2016, "Discriminative ability of reflex receptive fields to distinguish patients with acute and chronic low back pain"], ["Jos\u00e9 A Biurrun Manresa", 2016, "Discriminative ability of reflex receptive fields to distinguish patients with acute and chronic low back pain"], ["Christoph A Agten", 2016, "Discriminative ability of reflex receptive fields to distinguish patients with acute and chronic low back pain"], ["Michael Billinger", 2016, "Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial"], ["Christa Sch\u00f6nenberger", 2016, "Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial"], ["Franz Eberli", 2016, "Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial"], ["Christian Zanchin", 2016, "Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial"], ["Nils P Johnson", 2016, "A prospective natural history study of coronary atherosclerosis using fractional flow reserve"], ["Global Leaders", 2016, "Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale \u2026"], ["Hector M Garcia-Garcia", 2016, "Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale \u2026"], ["Susanne Hadorn", 2016, "External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre \u2026"], ["Jeffrey C Valentine", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Mohammed T Ansari", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Jonathan AC Sterne", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Craig R Ramsay", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Nancy D Berkman", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Douglas G Altman", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Hannah R Rothstein", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Penny F Whiting", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Holger J Sch\u00fcnemann", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Julian PT Higgins", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Lakhbir Sandhu", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Meera Viswanathan", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["David Henry", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Barnaby C Reeves", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Asbj\u00f8rn Hr\u00f3bjartsson", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Jelena Savovi\u0107", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Rachel Churchill", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Isabelle Boutron", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Yoon K Loke", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Lucy Turner", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Pasqualina L Santaguida", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Beverly Shea", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["An-Wen Chan", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Jonathan J Deeks", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Ian Shrier", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Jamie Kirkham", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Theresa D Pigott", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Deborah Regidor", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Elizabeth Waters", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Miguel A Hern\u00e1n", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Hugh Waddington", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["James R Carpenter", 2016, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions"], ["Paolo Bellotti", 2016, "Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial"], ["Eliano Navarese", 2016, "Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial"], ["Dennis Zavallonito-Parenti", 2016, "Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial"], ["Marco Ferlini", 2016, "Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial"], ["Salvatore Lerna", 2016, "Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial"], ["Nicolas M Van Mieghem", 2016, "Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial"], ["Marco Zimarino", 2016, "Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial"], ["Paolo Calabr\u00f3", 2016, "Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial"], ["L Raber", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["G Pedrazzini", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["C Von Birgelen", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["V Vukcevic", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["M Ostojic", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["H Kelbaek", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["A Baumbach", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["R Kornowski", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["TF Luscher", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["T Engstrom", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["D Tuller", 2016, "Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE \u2026"], ["J Rat-Wirtzler", 2016, "Diabetes and time course of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["R Piccolo", 2016, "Diabetes and time course of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["A Franzone", 2016, "Diabetes and time course of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["T Pilgrim", 2016, "Diabetes and time course of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["S Silber", 2016, "Diabetes and time course of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["S Stortecky", 2016, "Diabetes and time course of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["K Koskinas", 2016, "Diabetes and time course of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["Sigmund Silber", 2016, "Effect of diabetes mellitus on frequency of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["Julie Rat-Wirtzler", 2016, "Effect of diabetes mellitus on frequency of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"], ["Christina Moro", 2016, "Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention"], ["Fabienne Gartwyl", 2016, "Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention"], ["Bernhard Reimers", 2016, "Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials"], ["Sanjit S Jolly", 2016, "Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials"], ["Mitchell W Krucoff", 2016, "Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials"], ["Angelo Anzuini", 2016, "Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials"], ["Gianluigi Condorelli", 2016, "Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials"], ["Bruno R Da Costa", 2016, "Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials"], ["Terhi Vihervaara", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Markku S Nieminen", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Mika Hilvo", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Marko Sysi-Aho", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Kim Ekroos", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Hubert Scharnagl", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Dimple Kauhanen", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Juha Sinisalo", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Winfried M\u00e4rz", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Reini Hurme", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Thorsten Hornemann", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Eva Ringdal Pedersen", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Ottar Nyg\u00e5rd", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Matti Suoniemi", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Efthymia Vlachopoulou", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Grethe S Tell", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Marja-Liisa Lokki", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Reijo Laaksonen", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["Tatjana Stojakovic", 2016, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol"], ["S Trelle", 2016, "H\u00fcft-und Kniegelenksarthrose: NSARs vs. Paracetamol"], ["N Keller", 2016, "H\u00fcft-und Kniegelenksarthrose: NSARs vs. Paracetamol"], ["BR da Costa", 2016, "H\u00fcft-und Kniegelenksarthrose: NSARs vs. Paracetamol"], ["L Nartey", 2016, "H\u00fcft-und Kniegelenksarthrose: NSARs vs. Paracetamol"], ["S Wandel", 2016, "H\u00fcft-und Kniegelenksarthrose: NSARs vs. Paracetamol"], ["Stefan Bloechlinger", 2016, "Preprocedural high-sensitivity cardiac troponin T and clinical outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention"], ["Georg M Fiedler", 2016, "Preprocedural high-sensitivity cardiac troponin T and clinical outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention"], ["Ahmed A Khattab", 2016, "Preprocedural high-sensitivity cardiac troponin T and clinical outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention"], ["Andre Frenk", 2016, "Preprocedural high-sensitivity cardiac troponin T and clinical outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention"], ["Ashkan Yazdani", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Thomas Ischinger", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Hector M Garcia\u2010Garcia", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Yuki Ishibashi", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Marie\u2010Claude Morice", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Maik J Grundeken", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Samuel Copt", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Ton de Vries", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Volker Klauss", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Robbert J de Winter", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Carlo di Mario", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["Roberto Corti", 2016, "First generation versus second generation drug\u2010eluting stents for the treatment of bifurcations: 5\u2010year follow\u2010up of the LEADERS all\u2010comers randomized trial"], ["JD Carroll", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["DE Thaler", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["RW Smalling", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["M Reisman", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["B Meier", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["AJ Furlan", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["JL Saver", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["DM Kent", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["HP Mattle", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["R Ruthazer", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["IJ Dahabreh", 2016, "Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials (vol 67, pg 907, 2016)"], ["Reto Auer", 2016, "Health utility indexes in patients with acute coronary syndromes"], ["Mark Pletscher", 2016, "Health utility indexes in patients with acute coronary syndromes"], ["Fran\u00e7ois R Girardin", 2016, "Health utility indexes in patients with acute coronary syndromes"], ["Thomas V Perneger", 2016, "Health utility indexes in patients with acute coronary syndromes"], ["Julie Rat", 2016, "Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non\u2013ST-segment elevation acute coronary syndrome, and ST-segment elevation \u2026"], ["H Zeilhofer", 2016, "(415) Effect of the benzodiazepine clobazam in chronic low back pain and experimental pain modalities: a randomized placebo-controlled crossover study"], ["L Arendt-Nielsen", 2016, "(415) Effect of the benzodiazepine clobazam in chronic low back pain and experimental pain modalities: a randomized placebo-controlled crossover study"], ["Nikesh R Shrestha", 2016, "Prevalence of subclinical rheumatic heart disease in eastern Nepal: a school-based cross-sectional study"], ["Philip Urban", 2016, "Prevalence of subclinical rheumatic heart disease in eastern Nepal: a school-based cross-sectional study"], ["Hansj\u00f6rg Znoj", 2016, "Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis"], ["Thomas Munder", 2016, "Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis"], ["J\u00fcrgen Barth", 2016, "Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis"], ["Pim Cuijpers", 2016, "Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis"], ["Eveline N\u00fcesch", 2016, "Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis"], ["Heike Gerger", 2016, "Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis"], ["Rainer Zbinden", 2016, "Ultrathin strut biodegradable polymer sirolimus\u2010eluting stent versus durable\u2010polymer everolimus\u2010eluting stent for percutaneous coronary revascularization: 2\u2010year results of the \u2026"], ["Katazyrna Zuk", 2016, "Post\u2010procedural troponin elevation and clinical outcomes following transcatheter aortic valve implantation"], ["Henning Kelb\u00e6k", 2016, "Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography"], ["Erik J\u00f8rgensen", 2016, "Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography"], ["Aurelie Veugeois", 2016, "Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography"], ["Nicolas Amabile", 2016, "Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography"], ["Ulrik Abildgaard", 2016, "Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography"], ["Maria D Radu", 2016, "Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography"], ["Christophe Caussin", 2016, "Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography"], ["Thomas K\u00f6tter", 2016, "Eine systematische \u00dcbersicht mit Metaanalyse-Metamizol-assoziierte unerw\u00fcnschte Arzneimittelwirkungen*-Online ZFA"], ["Klaus Linde", 2016, "Eine systematische \u00dcbersicht mit Metaanalyse-Metamizol-assoziierte unerw\u00fcnschte Arzneimittelwirkungen*-Online ZFA"], ["Eva Blozik", 2016, "Eine systematische \u00dcbersicht mit Metaanalyse-Metamizol-assoziierte unerw\u00fcnschte Arzneimittelwirkungen*-Online ZFA"], ["Margrit F\u00e4ssler", 2016, "Eine systematische \u00dcbersicht mit Metaanalyse-Metamizol-assoziierte unerw\u00fcnschte Arzneimittelwirkungen*-Online ZFA"], ["Martin Scherer", 2016, "Eine systematische \u00dcbersicht mit Metaanalyse-Metamizol-assoziierte unerw\u00fcnschte Arzneimittelwirkungen*-Online ZFA"], ["Federico Carbone", 2016, "Prognostic value of PCSK9 levels in patients with acute coronary syndromes"], ["Nicolas Vuilleumier", 2016, "Prognostic value of PCSK9 levels in patients with acute coronary syndromes"], ["Sabine Mlekusch", 2016, "Conditioned pain modulation in patients with acute and chronic low back pain"], ["Alban Y Neziri", 2016, "Conditioned pain modulation in patients with acute and chronic low back pain"], ["G Gargiulo", 2016, "Radial versus femoral access for cardiac catheterisation-Authors' reply (vol 386, pg 2394, 2015)"], ["D Regidor", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["B Shea", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["PL Santaguida", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["H Waddington", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["GA Wells", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["I Shrier", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["YK Loke", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["JC Valentine", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["PF Whiting", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["HJ Sch\u00fcnemann", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["E Waters", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["L Turner", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["TD Pigott", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["P Tugwell", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["CR Ramsay", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["JPT Higgins", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["HR Rothstein", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["L Sandhu", 2016, "Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance"], ["P Stucki", 2016, "Mortality of patients with long term oxygen therapy due to chronic obstructive pulmonary disease-a Population based cohort study"], ["Nikolay Assenov Pavlov", 2016, "Mortality of patients with long term oxygen therapy due to chronic obstructive pulmonary disease-a Population based cohort study"], ["A Haynes", 2016, "Mortality of patients with long term oxygen therapy due to chronic obstructive pulmonary disease-a Population based cohort study"], ["Anne-Kathrin Brill", 2016, "Mortality of patients with long term oxygen therapy due to chronic obstructive pulmonary disease-a Population based cohort study"], ["L B\u00fctikofer", 2016, "Analgesic effect of single-dose imipramine on chronic low-back pain and quantitative sensory tests"], ["M Curatolo", 2016, "Analgesic effect of single-dose imipramine on chronic low-back pain and quantitative sensory tests"], ["A Limacher", 2016, "Analgesic effect of single-dose imipramine on chronic low-back pain and quantitative sensory tests"], ["U Stamer", 2016, "Analgesic effect of single-dose imipramine on chronic low-back pain and quantitative sensory tests"], ["J Schliessbach", 2016, "Analgesic effect of single-dose imipramine on chronic low-back pain and quantitative sensory tests"], ["Diethmar Antoni", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["Carlo Di Mario", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["Pedro Eerdmans", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["Gerrit-Anne Van Es", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["Rodrigo Estevez-Loureiro", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["Ton De Vries", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["Matteo Ghione", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["Hae Young Sohn", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["St\u00e9phanie Konik", 2016, "Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS \u2026"], ["Andre Vuilliomenet", 2016, "Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy \u2026"], ["Olga Endrich", 2016, "Revascularization Treatment of Emergency Patients with Acute ST-Segment Elevation Myocardial Infarction in Switzerland: Results from a Nationwide, Cross-Sectional Study in \u2026"], ["Claudia Berlin", 2016, "Revascularization Treatment of Emergency Patients with Acute ST-Segment Elevation Myocardial Infarction in Switzerland: Results from a Nationwide, Cross-Sectional Study in \u2026"], ["Jasvinder A Singh", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["David Tovey", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Louise Klokker", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Niti Goel", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Lyn March", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Caroline B Terwee", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Maarten Boers", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Robin Christensen", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Paula R Williamson", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Rachelle Buchbinder", 2015, "Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials"], ["Miguel Sousa Uva", 2015, "\u0420\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 ESC/EACTS \u043f\u043e \u0440\u0435\u0432\u0430\u0441\u043a\u0443\u043b\u044f\u0440\u0438\u0437\u0430\u0446\u0438\u0438 \u043c\u0438\u043e\u043a\u0430\u0440\u0434\u0430 2014"], ["David Paul Taggart", 2015, "\u0420\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 ESC/EACTS \u043f\u043e \u0440\u0435\u0432\u0430\u0441\u043a\u0443\u043b\u044f\u0440\u0438\u0437\u0430\u0446\u0438\u0438 \u043c\u0438\u043e\u043a\u0430\u0440\u0434\u0430 2014"], ["Lutz Buellesfeld", 2015, "Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation"], ["Lorenz Raber", 2015, "TCT-257 Frequency and clinical impact of prasugrel cessation after primary PCI in STEMI patients: a prospective cohort study"], ["Thomas Rosemann", 2015, "Template pour une carri\u00e8re acad\u00e9mique en m\u00e9decine de famille"], ["Johanna Sommer", 2015, "Template pour une carri\u00e8re acad\u00e9mique en m\u00e9decine de famille"], ["Thomas Bischoff", 2015, "Template pour une carri\u00e8re acad\u00e9mique en m\u00e9decine de famille"], ["A Zeller", 2015, "Template pour une carri\u00e8re acad\u00e9mique en m\u00e9decine de famille"], ["Ryan Tandjung", 2015, "Template pour une carri\u00e8re acad\u00e9mique en m\u00e9decine de famille"], ["George Sianos", 2015, "Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe \u2026"], ["Bruno da Costa", 2015, "Comparison of Surgical and Conservative Therapy of Lumbar Disc Herniation with Radicular Signs and Symptoms in a Quality Management Program: Abstract Number: 1414"], ["Anne Lyddiatt", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Ulrike Kaiser", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Damir Sapunar", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Ann M Taylor", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Raymond W Ostelo", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Kerry Scrivens", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Vibeke Strand", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Philip G Conaghan", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Philip J Mease", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Lee S Simon", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Jason W Busse", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Kristine Phillips", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Clifton O Bingham", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Dorcas E Beaton", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Shawna Grosskleg", 2015, "Current state of reporting pain outcomes in Cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda"], ["Stephane Noble", 2015, "Procedural results and clinical outcomes of transcatheter aortic valve implantation in Switzerland: an observational cohort study of Sapien 3 versus Sapien XT transcatheter \u2026"], ["Giovanni Pedrazzini", 2015, "Procedural results and clinical outcomes of transcatheter aortic valve implantation in Switzerland: an observational cohort study of Sapien 3 versus Sapien XT transcatheter \u2026"], ["Ronald K Binder", 2015, "Procedural results and clinical outcomes of transcatheter aortic valve implantation in Switzerland: an observational cohort study of Sapien 3 versus Sapien XT transcatheter \u2026"], ["Franz W Amann", 2015, "Procedural results and clinical outcomes of transcatheter aortic valve implantation in Switzerland: an observational cohort study of Sapien 3 versus Sapien XT transcatheter \u2026"], ["Fabienne Luterbacher", 2015, "Validation of the valve academic research consortium bleeding definition in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation"], ["Christian M Schmied", 2015, "Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes"], ["Jacques Cornuz", 2015, "Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes"], ["Pierre Vogt", 2015, "Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes"], ["Franz H Messerli", 2015, "BEST\u2014When a Study Falls Short of Its Acronym"], ["Alessandra Repetto", 2015, "Bivalirudin or unfractionated heparin in acute coronary syndromes"], ["Arnoud van\u2019t Hof", 2015, "Bivalirudin or unfractionated heparin in acute coronary syndromes"], ["Miodrag Ostoijic", 2015, "Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials"], ["Antonio Serra", 2015, "Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials"], ["Giulio Stefanini", 2015, "Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials"], ["Andr\u00e9s I\u00f1iguez", 2015, "Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials"], ["Rosana Hernandez-Antolin", 2015, "Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials"], ["Sandro Baumgartner", 2015, "The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study"], ["Konstantinos C Siontis", 2015, "Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis"], ["Mar\u00eda J P\u00e9rez-Vizcayno", 2015, "Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis"], ["Sibylle Kozek Langenecker", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Adam Torbicki", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Per Anton Sirnes", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Maurizio Solca", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Luc Pierard", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Edoardo de Robertis", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Stuart Pocock", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Arno W Hoes", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Massimo F Piepoli", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Vasilis Voudris", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Stefan Anker", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Paulus Kirchhof", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["David Hasdai", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Dan Longrois", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Andreas Hoeft", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Ian Ford", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Stephan Achenbach", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Ales Linhart", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Jean Fran\u00e7ois Brichant", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Hans Erik B\u00f8tker", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Juan Luis Tamargo", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Petros Nihoyannopoulos", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Christi Deaton", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Christian Funck-Brentano", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Steen Dalby Kristensen", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Josef Wichelewski", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Jose Ram\u00f3n Gonzalez-Juanatey", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Guy Robert Heyndrickx", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Cetin Erol", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Keld Per Kjeldsen", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Roberto Ferrari", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Robert Fagard", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["Stefan De Hert", 2015, "2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management"], ["P Kraehenmann", 2015, "Echocardiographic screening among schoolchildren in Peru: prevalence of rheumatic heart disease according to different definitions and incidental findings"], ["J Mercado", 2015, "Echocardiographic screening among schoolchildren in Peru: prevalence of rheumatic heart disease according to different definitions and incidental findings"], ["M Rothenbuehler", 2015, "Echocardiographic screening among schoolchildren in Peru: prevalence of rheumatic heart disease according to different definitions and incidental findings"], ["R Kurmann", 2015, "Echocardiographic screening among schoolchildren in Peru: prevalence of rheumatic heart disease according to different definitions and incidental findings"], ["P Torres", 2015, "Echocardiographic screening among schoolchildren in Peru: prevalence of rheumatic heart disease according to different definitions and incidental findings"], ["F Zuercher", 2015, "Echocardiographic screening among schoolchildren in Peru: prevalence of rheumatic heart disease according to different definitions and incidental findings"], ["F Islas", 2015, "Echocardiographic screening among schoolchildren in Peru: prevalence of rheumatic heart disease according to different definitions and incidental findings"], ["J Rat", 2015, "Comparative effectiveness and safety of new versus earlygeneration drugeluting stents according to the complexity of coronary artery disease. A patientlevel pooled analysis of \u2026"], ["T Pigrim", 2015, "Comparative effectiveness and safety of new versus earlygeneration drugeluting stents according to the complexity of coronary artery disease. A patientlevel pooled analysis of \u2026"], ["KC Koskinas", 2015, "Association between serum levels of C-reactive protein and changes of plaque composition in non-infarct-related coronary arteries following high-intensity statin therapy \u2026"], ["HM Garcia-Grcia", 2015, "Association between serum levels of C-reactive protein and changes of plaque composition in non-infarct-related coronary arteries following high-intensity statin therapy \u2026"], ["M Taniwaki", 2015, "Association between serum levels of C-reactive protein and changes of plaque composition in non-infarct-related coronary arteries following high-intensity statin therapy \u2026"], ["S Zaugg", 2015, "Association between serum levels of C-reactive protein and changes of plaque composition in non-infarct-related coronary arteries following high-intensity statin therapy \u2026"], ["A Moschovitis", 2015, "Association between serum levels of C-reactive protein and changes of plaque composition in non-infarct-related coronary arteries following high-intensity statin therapy \u2026"], ["T Zanchin", 2015, "Prevalence and prognostic significance of preprocedural high-sensitivity cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous \u2026"], ["C Moro", 2015, "Prevalence and prognostic significance of preprocedural high-sensitivity cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous \u2026"], ["N Curzen", 2015, "FFR risk continuum for target vessel failure: a FAME 2 trial subanalysis"], ["G Toth", 2015, "FFR risk continuum for target vessel failure: a FAME 2 trial subanalysis"], ["NP Johnson", 2015, "FFR risk continuum for target vessel failure: a FAME 2 trial subanalysis"], ["O Muller", 2015, "Factors associated with improvement of depression after acute coronary syndromes"], ["R Auer", 2015, "Factors associated with improvement of depression after acute coronary syndromes"], ["N Pandey", 2015, "Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal"], ["TM Pilgrim", 2015, "Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal"], ["NR Shrestha", 2015, "Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal"], ["P Urban", 2015, "Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal"], ["P Karki", 2015, "Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal"], ["R Mahto", 2015, "Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal"], ["K Gurung", 2015, "Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal"], ["K Agrawal", 2015, "Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal"], ["Manuel Blum", 2015, "Low statin use in adults hospitalized with acute coronary syndrome"], ["Kevin Selby", 2015, "Low statin use in adults hospitalized with acute coronary syndrome"], ["Pedro Marques-Vidal", 2015, "Low statin use in adults hospitalized with acute coronary syndrome"], ["Miodrag Ostojic", 2015, "Safety of Prasugrel loading doses in patients pre-loaded with Clopidogrel in the setting of primary percutaneous coronary intervention: results of a nonrandomized observational \u2026"], ["COMFORTABLE and SPUM-ACS Trial Investigators", 2015, "Safety of Prasugrel loading doses in patients pre-loaded with Clopidogrel in the setting of primary percutaneous coronary intervention: results of a nonrandomized observational \u2026"], ["Clemens von Birgelen", 2015, "Safety of Prasugrel loading doses in patients pre-loaded with Clopidogrel in the setting of primary percutaneous coronary intervention: results of a nonrandomized observational \u2026"], ["Vasim Farooq", 2015, "Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention"], ["Bindu Kalesan", 2015, "Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention"], ["Kay-Tee Khaw", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Alexandra P Bremner", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Mari Hoff", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Manuel R Blum", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Jacobijn Gussekloo", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Howard A Fink", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Arnuf Langhammer", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Robin P Peeters", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Patricia M Kearney", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Andr\u00e9 G Uitterlinden", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Graham R Williams", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["John P Walsh", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Graziano Ceresini", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Anne R Cappola", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Fernando Rivadeneira", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Tinh-Hai Collet", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Robert N Luben", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["David J Stott", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Apostolos Gogakos", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Christina D Wirth", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Misa Imaizumi", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Elsa S Strotmeyer", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Luigi Ferrucci", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Erin R Wallace", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Richard Eastell", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Bj\u00f8rn O \u00c5svold", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Wendy PJ Den Elzen", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Rudi GJ Westendorp", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Douglas C Bauer", 2015, "Subclinical thyroid dysfunction and fracture risk: a meta-analysis"], ["Antoinette de Waha", 2015, "Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of \u2026"], ["Lamin A King", 2015, "Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of \u2026"], ["Stefan Sauerland", 2015, "Letter regarding \u201cThe effects of arthroscopic joint debridement in the knee osteoarthritis: results of a meta-analysis\u201d"], ["Frank Peinemann", 2015, "Letter regarding \u201cThe effects of arthroscopic joint debridement in the knee osteoarthritis: results of a meta-analysis\u201d"], ["Paul A Dieppe", 2015, "Association of radiographic osteoarthritis, pain on passive movement and knee range of motion: A cross-sectional study"], ["Roger Hilfiker", 2015, "Association of radiographic osteoarthritis, pain on passive movement and knee range of motion: A cross-sectional study"], ["Javaid Iqbal", 2015, "Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction"], ["Gerrit-Anne van Es", 2015, "Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction"], ["Yao-Jun Zhang", 2015, "Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction"], ["Rana Saitta", 2015, "Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction"], ["Thierry Lef\u00e8vre", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Johannes Bilger", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Bernhard Witzenbichler", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Christophe Piot", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Paul Barragan", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Gert Richardt", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Henrik Schneider", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Ron Waksman", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["B\u00e9la Merkely", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Karl Stangl", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Paul Erne", 2015, "Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial"], ["Jean-Christophe Stauffer", 2015, "Five-year results of a randomised comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularisation."], ["Ali Reza Garachemani", 2015, "Five-year results of a randomised comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularisation."], ["John Carroll", 2015, "Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis"], ["Marius Hornung", 2015, "Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis"], ["Horst Sievert", 2015, "Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis"], ["SV Rao", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["F Varbella", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["P Rubartelli", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["A Repetto", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["P Tosi", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["P Calabro", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["N de Cesare", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["S Ierna", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["A Zingarelli", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["S Rigattieri", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["E Frigoli", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["S Tresoldi", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["S Leonardi", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["P Sganzerla", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["M Rothenbuhler", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["C Briguori", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["T Zaro", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["M Galli", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["U Limbruno", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["B Cortese", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["A Lupi", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["S Colangelo", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["G Esposito", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["S Brugaletta", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["A Ausiello", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["P Presbitero", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["A Santarelli", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["C Palmieri", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["G Ando", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["G Sardella", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["M Nazzaro", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["A Gagnor", 2015, "Investigators M. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["Uva M Sousa", 2015, "2014 ESC/EACTS guidelines on myocardial revascularization."], ["Anna Petronio", 2015, "Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial"], ["M Mueller", 2015, "Predictive value of receptive fields for persistence of pain after spinal surgery: a cohort study"], ["F Treichel", 2015, "Predictive value of receptive fields for persistence of pain after spinal surgery: a cohort study"], ["Ibrahim Al-Rashdan", 2015, "Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus drug-eluting stent in coronary disease)."], ["Rodney De Palma", 2015, "Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus drug-eluting stent in coronary disease)."], ["AMIS Plus Investigators", 2015, "Age-and gender-related disparities in primary percutaneous coronary interventions for acute ST-segment elevation myocardial infarction"], ["Dragana Radovanovic", 2015, "Age-and gender-related disparities in primary percutaneous coronary interventions for acute ST-segment elevation myocardial infarction"], ["Jorge Mercado", 2015, "Screening for rheumatic heart disease among Peruvian children: a two-stage sampling observational study"], ["Pedro Torres", 2015, "Screening for rheumatic heart disease among Peruvian children: a two-stage sampling observational study"], ["Reto Kurmann", 2015, "Screening for rheumatic heart disease among Peruvian children: a two-stage sampling observational study"], ["Fabian Z\u00fcrcher", 2015, "Screening for rheumatic heart disease among Peruvian children: a two-stage sampling observational study"], ["Nassip Llerena", 2015, "Screening for rheumatic heart disease among Peruvian children: a two-stage sampling observational study"], ["Fabian Islas", 2015, "Screening for rheumatic heart disease among Peruvian children: a two-stage sampling observational study"], ["Peter Kr\u00e4henmann", 2015, "Screening for rheumatic heart disease among Peruvian children: a two-stage sampling observational study"], ["Maria G Silletta", 2015, "Intra\u2010articular corticosteroid for knee osteoarthritis"], ["Roland Fischer", 2015, "Intra\u2010articular corticosteroid for knee osteoarthritis"], ["Osman Ceylan", 2015, "Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality"], ["Lars Englberger", 2015, "Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality"]]}